Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Theivanthiran, Balamayoora, Kathy S. Evans, Nicholas C. DeVito, Michael Plebanek, Michael Sturdivant, Luke P. Wachsmuth, April Ks Salama, et al. “A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.” J Clin Invest 130, no. 5 (May 1, 2020): 2570–86. https://doi.org/10.1172/JCI133055.

PMID
32017708
Full Text

Schoonderwoerd, Mark Ja, Maaike Fm Koops, Ricardo A. Angela, Bryan Koolmoes, Melpomeni Toitou, Madelon Paauwe, Marieke C. Barnhoorn, et al. “Targeting endoglin expressing regulatory T cells in the tumor microenvironment enhances the effect of PD1 checkpoint inhibitor immunotherapy.” Clin Cancer Res, April 24, 2020. https://doi.org/10.1158/1078-0432.CCR-19-2889.

PMID
32332012
Full Text

Alvarez Secord, Angeles, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, et al. “Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1288–96. https://doi.org/10.1158/1078-0432.CCR-19-0226.

PMID
31919136
Full Text

Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol, March 12, 2020. https://doi.org/10.1002/ajh.25781.

PMID
32162718
Full Text

Siamakpour-Reihani, Sharareh, Lauren Patterson Cobb, Chen Jiang, Dadong Zhang, Rebecca A. Previs, Kouros Owzar, Andrew B. Nixon, and Angeles Alvarez Secord. “Differential expression of immune related genes in high-grade ovarian serous carcinoma.” Gynecol Oncol 156, no. 3 (March 2020): 662–68. https://doi.org/10.1016/j.ygyno.2019.12.019.

PMID
31918995
Full Text

Reed, Christopher Robert, Christopher Cameron McCoy, Uttara Nag, Andrew B. Nixon, James Otto, Jeffrey Harold Lawson, Andrew J. Lodge, Joseph W. Turek, and Elisabeth Tomlinson Tracy. “Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools.” J Surg Res 246 (February 2020): 83–92. https://doi.org/10.1016/j.jss.2019.08.019.

PMID
31562990
Full Text

Nixon, Andrew B., Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang, and Catherine Fleener. “Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?” J Immunother Cancer 7, no. 1 (November 27, 2019): 325. https://doi.org/10.1186/s40425-019-0799-2.

PMID
31775882
Full Text

Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.

PMID
31675952
Full Text

Arrillaga-Romany, Isabel, Solmaz Sahebjam, David Picconi, Jian Campian, Pierre Giglio, Jan Drappatz, Robert Aiken, et al. “A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 21:27–27. OXFORD UNIV PRESS INC, 2019.

Scholars@Duke

George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.

PMID
31497882
Full Text

Pages